<p>國會資產管理公司在最近向證券交易委員會（SEC）提交的 13F 表格中披露，第三季度其在 Inspire Medical Systems, Inc.（紐約證券交易所代碼：INSP - 免費報告）的持股減少了 96.4%。該基金在出售了 359,846 股後，持有該公司 13,501 股股票。截至其最近向證券交易委員會（SEC）提交的文件，國會資產管理公司在 Inspire Medical Systems 的持股價值為 1,002,000 美元。</p>
<ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
<p>其他對沖基金和機構投資者最近也對該公司的持倉進行了調整。高盛集團在第一季度將其在 Inspire Medical Systems 的持倉提高了 57.9%。高盛集團目前持有該公司 51,422 股股票，價值 8,190,000 美元，此前在該期間內又增持了 18,857 股。德克薩斯州永久學校基金公司在第二季度將其在 Inspire Medical Systems 的持倉增加了 42.2%。德克薩斯州永久學校基金公司目前持有該公司 40,042 股股票，價值 5,196,000 美元，此前又購買了 11,892 股。Nordea Investment Management AB 在第二季度購買了 Inspire Medical Systems 的新股份，價值 1,634,000 美元。Bayforest Capital Ltd 在第一季度將其在 Inspire Medical Systems 的持倉增加了 2,465.9%。Bayforest Capital Ltd 目前持有該公司 5,491 股股票，價值 875,000 美元，此前在上個季度又購買了 5,277 股。最後，CW Advisors LLC 在第二季度將其在 Inspire Medical Systems 的持倉提高了 45.3%。CW Advisors LLC 目前持有該公司 49,960 股股票，價值 6,484,000 美元，此前又購買了 15,576 股。94.91% 的股票由機構投資者和對沖基金持有。</p>
<h2>Inspire Medical Systems 股票表現</h2>
<p>INSP 的股票在週二開盤價為 97.70 美元。該公司的市值為 28.4 億美元，市盈率為 66.46，市盈增長比率為 11.12，貝塔值為 0.69。Inspire Medical Systems, Inc.的 52 周最低價為 70.77 美元，52 周最高價為 216.01 美元。該股票的 50 日移動平均價格為 99.98 美元，200 日移動平均價格為 102.96 美元。</p>
<ul>
<li>Inspire Medical 在突破後上漲 15%，分析師稱其為買入</li>
</ul>
<p>Inspire Medical Systems（紐約證券交易所代碼：INSP - 獲取免費報告）最後一次公佈財報是在 11 月 3 日，週一。該公司報告本季度每股收益（EPS）為 0.38 美元，超出市場共識預期的（0.15 美元）0.53 美元。該公司本季度的收入為 2.245 億美元，而分析師預期為 2.2039 億美元。Inspire Medical Systems 的股本回報率為 9.41%，淨利潤率為 5.05%。Inspire Medical Systems 的季度收入同比增長 10.5%。在去年同期，該公司每股收益為 0.60 美元。平均而言，股票分析師預測 Inspire Medical Systems, Inc.今年將發佈 2.16 美元的每股收益。</p>
<h2>分析師評級變動</h2>
<p>幾家券商最近對 INSP 發表了評論。瑞穗證券在 12 月 17 日的研究報告中將 Inspire Medical Systems 的目標價格從 110.00 美元上調至 130.00 美元，並給予該公司 “跑贏大盤” 的評級。Truist Financial 在 11 月 26 日的報告中將 Inspire Medical Systems 的評級從 “持有” 上調至 “買入”，並將該股票的目標價格從 128.00 美元上調至 165.00 美元。Stifel Nicolaus 在 11 月 24 日的報告中為 Inspire Medical Systems 設定了 110.00 美元的價格目標，並給予該公司 “買入” 評級。Weiss Ratings 在 12 月 10 日的研究報告中重申了對 Inspire Medical Systems 股票的 “賣出（d+）” 評級。最後，富國銀行在 11 月 4 日的報告中將 Inspire Medical Systems 的評級從 “等權重” 上調至 “超配”，並將該股票的目標價格從 101.00 美元下調至 90.00 美元。共有 11 位分析師對該股票給予了買入評級，7 位給予了持有評級，1 位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價格為 138.88 美元。</p>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p><strong>閲讀我們關於 Inspire Medical Systems 的最新研究報告</strong></p>
<h2>內部活動</h2>
<p>在其他新聞中，董事 Shawn Mccormick 在 11 月 28 日的交易中出售了 2,000 股該股票。該股票以 127.48 美元的平均價格出售，總價值為 254,960.00 美元。出售完成後，該董事在公司持有 26,046 股股票，價值 3,320,344.08 美元。這代表其持股減少了 7.13%。該出售在向 SEC 提交的文件中披露，文件可在此鏈接查看。當前 2.30% 的股票由內部人士持有。</p>
<h2>Inspire Medical Systems 新聞摘要</h2>
<p>以下是本週影響 Inspire Medical Systems 的主要新聞故事：</p>
<ul>
<li>積極情緒：Zacks 發佈了一份看漲報告，認為由於 Inspire V 臨牀數據強勁、報銷可見性改善和成本控制，INSP 仍然值得持有，儘管面臨庫存和 GLP-1 的挑戰。Zacks：維持 INSP 股票</li>
<li>積極情緒：報告顯示分析師提高了目標價（MSN 報道提高了 12.65% 至 $144.32），這表明在近期疲軟後，賣方對上漲的信心有所增強。MSN：目標價上調</li>
<li>消極情緒：今天提交或宣佈了多起證券集體訴訟和投資者通知，指控與產品延遲、醫療保險計費軟件問題和 Inspire V 庫存過剩相關的披露失敗；數十家原告律師事務所正在徵求主原告動議，截止日期為 2026 年 1 月 5 日——這增加了法律風險、潛在和解以及短期股價壓力。BLB&amp;G 提交 Rosen 通知 Hagens Berman 警報</li>
<li>消極情緒：許多其他原告律師事務所（BFA Law、Glancy Prongay &amp; Murray、The Gross Law Firm、Faruqi &amp; Faruqi、Schall、Bronstein Gewirtz 等）發佈提醒，鼓勵投資者尋求主原告角色——這一系列通知加大了頭條風險，並可能在訴訟展開時延長波動性。MarketWatch / BFA Glancy 通知</li>
</ul>
<h2>關於 Inspire Medical Systems</h2>
<p>(免費報告)</p>
<p>Inspire Medical Systems, Inc 是一家醫療科技公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品 Inspire® 系統，通過對舌下神經進行定向刺激，以維持睡眠期間的氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
<p>Inspire 系統由一個可植入的脈衝發生器、一個監測呼吸模式的傳感導線和一個激活舌下神經的刺激導線組成。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Inspire Medical Systems</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>最後的黃金牛市</li>
</ul>
<p><strong>想看看其他對 INSP 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Inspire Medical Systems, Inc. (NYSE:INSP - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Inspire Medical Systems 嗎？</h2>
<p>在考慮投資 Inspire Medical Systems 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄向客户推薦在更廣泛市場關注之前立即購買……而 Inspire Medical Systems 並不在名單上。</p>
<p>儘管 Inspire Medical Systems 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

啟迪醫療

<p>國會資產管理公司在第三季度大幅減少了對啓迪醫療的持股，降幅達到 96.4%，目前持有價值 100 萬美元的股份。其他機構投資者也進行了頭寸調整，高盛將其持股增加了 57.9%。啓迪醫療的股票表現顯示市值為 28.4 億美元，並且最近的財報超出預期。分析師的評級意見不一，普遍共識為 “適度買入”，目標價格為 138.88 美元</p>

<p>Congress Asset Management Co. trimmed its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 96.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,501 shares of the company's stock after selling 359,846 shares during the quarter. Congress Asset Management Co.'s holdings in Inspire Medical Systems were worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>國會資產管理公司在最近向證券交易委員會（SEC）提交的 13F 表格中披露，第三季度其在 Inspire Medical Systems, Inc.（紐約證券交易所代碼：INSP - 免費報告）的持股減少了 96.4%。該基金在出售了 359,846 股後，持有該公司 13,501 股股票。截至其最近向證券交易委員會（SEC）提交的文件，國會資產管理公司在 Inspire Medical Systems 的持股價值為 1,002,000 美元。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock valued at $8,190,000 after acquiring an additional 18,857 shares during the period. Texas Permanent School Fund Corp grew its holdings in Inspire Medical Systems by 42.2% in the second quarter. Texas Permanent School Fund Corp now owns 40,042 shares of the company's stock worth $5,196,000 after purchasing an additional 11,892 shares during the period. Nordea Investment Management AB bought a new stake in Inspire Medical Systems in the second quarter valued at $1,634,000. Bayforest Capital Ltd increased its stake in Inspire Medical Systems by 2,465.9% in the first quarter. Bayforest Capital Ltd now owns 5,491 shares of the company's stock valued at $875,000 after purchasing an additional 5,277 shares in the last quarter. Finally, CW Advisors LLC raised its holdings in shares of Inspire Medical Systems by 45.3% during the second quarter. CW Advisors LLC now owns 49,960 shares of the company's stock valued at $6,484,000 after purchasing an additional 15,576 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者最近也對該公司的持倉進行了調整。高盛集團在第一季度將其在 Inspire Medical Systems 的持倉提高了 57.9%。高盛集團目前持有該公司 51,422 股股票，價值 8,190,000 美元，此前在該期間內又增持了 18,857 股。德克薩斯州永久學校基金公司在第二季度將其在 Inspire Medical Systems 的持倉增加了 42.2%。德克薩斯州永久學校基金公司目前持有該公司 40,042 股股票，價值 5,196,000 美元，此前又購買了 11,892 股。Nordea Investment Management AB 在第二季度購買了 Inspire Medical Systems 的新股份，價值 1,634,000 美元。Bayforest Capital Ltd 在第一季度將其在 Inspire Medical Systems 的持倉增加了 2,465.9%。Bayforest Capital Ltd 目前持有該公司 5,491 股股票，價值 875,000 美元，此前在上個季度又購買了 5,277 股。最後，CW Advisors LLC 在第二季度將其在 Inspire Medical Systems 的持倉提高了 45.3%。CW Advisors LLC 目前持有該公司 49,960 股股票，價值 6,484,000 美元，此前又購買了 15,576 股。94.91% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Inspire Medical Systems Stock Performance</h2>
<div class="lb-trans"><h2>Inspire Medical Systems 股票表現</h2>
</div><p>Shares of INSP opened at $97.70 on Tuesday. The firm has a market capitalization of $2.84 billion, a P/E ratio of 66.46, a P/E/G ratio of 11.12 and a beta of 0.69. Inspire Medical Systems, Inc. has a 52 week low of $70.77 and a 52 week high of $216.01. The stock has a 50 day moving average price of $99.98 and a two-hundred day moving average price of $102.96.</p>
<div class="lb-trans"><p>INSP 的股票在週二開盤價為 97.70 美元。該公司的市值為 28.4 億美元，市盈率為 66.46，市盈增長比率為 11.12，貝塔值為 0.69。Inspire Medical Systems, Inc.的 52 周最低價為 70.77 美元，52 周最高價為 216.01 美元。該股票的 50 日移動平均價格為 99.98 美元，200 日移動平均價格為 102.96 美元。</p>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Inspire Medical 在突破後上漲 15%，分析師稱其為買入</li>
</ul>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.53. The company had revenue of $224.50 million for the quarter, compared to analysts' expectations of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.Inspire Medical Systems's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. On average, equities analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>Inspire Medical Systems（紐約證券交易所代碼：INSP - 獲取免費報告）最後一次公佈財報是在 11 月 3 日，週一。該公司報告本季度每股收益（EPS）為 0.38 美元，超出市場共識預期的（0.15 美元）0.53 美元。該公司本季度的收入為 2.245 億美元，而分析師預期為 2.2039 億美元。Inspire Medical Systems 的股本回報率為 9.41%，淨利潤率為 5.05%。Inspire Medical Systems 的季度收入同比增長 10.5%。在去年同期，該公司每股收益為 0.60 美元。平均而言，股票分析師預測 Inspire Medical Systems, Inc.今年將發佈 2.16 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several brokerages have recently commented on INSP. Mizuho raised their target price on Inspire Medical Systems from $110.00 to $130.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 17th. Truist Financial upgraded Inspire Medical Systems from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their price target for the stock from $128.00 to $165.00 in a report on Wednesday, November 26th. Stifel Nicolaus set a $110.00 price objective on Inspire Medical Systems and gave the company a &#34;buy&#34; rating in a report on Monday, November 24th. Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of Inspire Medical Systems in a research report on Wednesday, December 10th. Finally, Wells Fargo &amp; Company upgraded Inspire Medical Systems from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and cut their target price for the stock from $101.00 to $90.00 in a report on Tuesday, November 4th. Eleven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $138.88.</p>
<div class="lb-trans"><p>幾家券商最近對 INSP 發表了評論。瑞穗證券在 12 月 17 日的研究報告中將 Inspire Medical Systems 的目標價格從 110.00 美元上調至 130.00 美元，並給予該公司 “跑贏大盤” 的評級。Truist Financial 在 11 月 26 日的報告中將 Inspire Medical Systems 的評級從 “持有” 上調至 “買入”，並將該股票的目標價格從 128.00 美元上調至 165.00 美元。Stifel Nicolaus 在 11 月 24 日的報告中為 Inspire Medical Systems 設定了 110.00 美元的價格目標，並給予該公司 “買入” 評級。Weiss Ratings 在 12 月 10 日的研究報告中重申了對 Inspire Medical Systems 股票的 “賣出（d+）” 評級。最後，富國銀行在 11 月 4 日的報告中將 Inspire Medical Systems 的評級從 “等權重” 上調至 “超配”，並將該股票的目標價格從 101.00 美元下調至 90.00 美元。共有 11 位分析師對該股票給予了買入評級，7 位給予了持有評級，1 位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價格為 138.88 美元。</p>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p><strong>Read Our Latest Research Report on Inspire Medical Systems</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Inspire Medical Systems 的最新研究報告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, Director Shawn Mccormick sold 2,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the sale, the director owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Shawn Mccormick 在 11 月 28 日的交易中出售了 2,000 股該股票。該股票以 127.48 美元的平均價格出售，總價值為 254,960.00 美元。出售完成後，該董事在公司持有 26,046 股股票，價值 3,320,344.08 美元。這代表其持股減少了 7.13%。該出售在向 SEC 提交的文件中披露，文件可在此鏈接查看。當前 2.30% 的股票由內部人士持有。</p>
</div><h2>Inspire Medical Systems News Summary</h2>
<div class="lb-trans"><h2>Inspire Medical Systems 新聞摘要</h2>
</div><p>Here are the key news stories impacting Inspire Medical Systems this week:</p>
<div class="lb-trans"><p>以下是本週影響 Inspire Medical Systems 的主要新聞故事：</p>
</div><ul>
<li>Positive Sentiment: Zacks published a bullish note arguing INSP remains worth holding due to strong Inspire V clinical data, improving reimbursement visibility and cost control despite inventory and GLP‑1 headwinds. Zacks: Retain INSP Stock</li>
<li>Positive Sentiment: An analyst price‑target increase was reported (MSN coverage of a 12.65% raise to $144.32), signaling some sell‑side conviction on upside after recent weakness. MSN: Price Target Increase</li>
<li>Negative Sentiment: Multiple securities class actions and investor notices were filed or announced today, alleging disclosure failures tied to product delays, Medicare billing software issues and an Inspire V inventory glut; dozens of plaintiff firms are soliciting lead‑plaintiff motions with a January 5, 2026 deadline — this increases legal exposure, potential settlements and short‑term share pressure. BLB&amp;G FilingRosen NoticeHagens Berman Alert</li>
<li>Negative Sentiment: Numerous additional plaintiff firms (BFA Law, Glancy Prongay &amp; Murray, The Gross Law Firm, Faruqi &amp; Faruqi, Schall, Bronstein Gewirtz, etc.) issued reminders encouraging investors to seek lead‑plaintiff roles — the flurry of notices amplifies headline risk and could prolong volatility as the litigation unfolds. MarketWatch / BFAGlancy Notice</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Zacks 發佈了一份看漲報告，認為由於 Inspire V 臨牀數據強勁、報銷可見性改善和成本控制，INSP 仍然值得持有，儘管面臨庫存和 GLP-1 的挑戰。Zacks：維持 INSP 股票</li>
<li>積極情緒：報告顯示分析師提高了目標價（MSN 報道提高了 12.65% 至 $144.32），這表明在近期疲軟後，賣方對上漲的信心有所增強。MSN：目標價上調</li>
<li>消極情緒：今天提交或宣佈了多起證券集體訴訟和投資者通知，指控與產品延遲、醫療保險計費軟件問題和 Inspire V 庫存過剩相關的披露失敗；數十家原告律師事務所正在徵求主原告動議，截止日期為 2026 年 1 月 5 日——這增加了法律風險、潛在和解以及短期股價壓力。BLB&amp;G 提交 Rosen 通知 Hagens Berman 警報</li>
<li>消極情緒：許多其他原告律師事務所（BFA Law、Glancy Prongay &amp; Murray、The Gross Law Firm、Faruqi &amp; Faruqi、Schall、Bronstein Gewirtz 等）發佈提醒，鼓勵投資者尋求主原告角色——這一系列通知加大了頭條風險，並可能在訴訟展開時延長波動性。MarketWatch / BFA Glancy 通知</li>
</ul>
</div><h2>About Inspire Medical Systems</h2>
<div class="lb-trans"><h2>關於 Inspire Medical Systems</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>Inspire Medical Systems, Inc 是一家醫療科技公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品 Inspire® 系統，通過對舌下神經進行定向刺激，以維持睡眠期間的氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>Inspire 系統由一個可植入的脈衝發生器、一個監測呼吸模式的傳感導線和一個激活舌下神經的刺激導線組成。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Inspire Medical Systems</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>最後的黃金牛市</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding INSP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 INSP 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Inspire Medical Systems, Inc. (NYSE:INSP - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=INSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Inspire Medical Systems 嗎？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Inspire Medical Systems 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄向客户推薦在更廣泛市場關注之前立即購買……而 Inspire Medical Systems 並不在名單上。</p>
</div><p>While Inspire Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Inspire Medical Systems 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Congress Asset Management Co.在啓迪醫療系統公司（Inspire Medical Systems, Inc. $INSP）中持有價值 100 萬美元的股票